Moreover, the co-expression of IDO-1 and PD-L1 might be related to the enhanced anti-tumor efficacy in NSCLC clinical trials with dual blocking of PD-1/PD-L1 and IDO-1154. The gene discussed is IDO1; the disease is non-small cell lung carcinoma.